Apollomics (APLM) Current Leases (2021 - 2025)

Apollomics (APLM) posted quarterly Current Leases of $209000.0 for Q4 2025, down 45.71% quarter-over-quarter from $385000.0 in Q2 2023.

Apollomics (APLM) Current Leases (2021 - 2025) Analysis & Trends

Apollomics (APLM) has reported Current Leases for 4 consecutive years, with $209000.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Current Leases changed N/A year-over-year to $209000.0; the TTM figure through Dec 2025 stood at $209000.0 (changed N/A YoY), while the FY2025 annual figure was $209000.0, changed N/A from the prior year.
Current Leases fell to $209000.0 in Q4 2025 per APLM's latest filing, from $385000.0 in the prior quarter.
Across five years, Current Leases topped out at $614000.0 in Q4 2022 and bottomed at $209000.0 in Q4 2025.
Historically, Current Leases has averaged $429000.0 across 4 years, with a median of $446500.0 in 2021.
On a YoY basis, Current Leases climbed as much as 20.87% in 2022 and fell as far as 20.87% in 2022.
Apollomics' Current Leases stood at $508000.0 in 2021, then climbed by 20.87% to $614000.0 in 2022, then slumped by 37.3% to $385000.0 in 2023, then plunged by 45.71% to $209000.0 in 2025.
Business Quant data shows APLM's Current Leases at $209000.0 in Q4 2025, $385000.0 in Q2 2023, and $614000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	139.65 Bn	131.79 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.08 Bn	78.09 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	-
4	Moderna	63.25 Bn	58.11 Bn	52.00 Mn	-
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn	21.95 Mn
6	Alnylam Pharmaceuticals	31.26 Bn	27.95 Bn	992.69 Mn	45.93 Mn
7	BioNTech SE	28.96 Bn	10.57 Bn	668.28 Mn	-
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn	6.27 Mn
9	Royalty Pharma	27.19 Bn	26.35 Bn	-	-
10	Apollomics	33.16 Mn	29.88 Mn	-	209,000.00

Download Data